Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory neuroblastoma.

被引：1

作者：

Zhu, Jia ^{[1
]}

Zhen, Zijun ^{[1
]}

Wang, Juan ^{[1
]}

Chen, Tingting ^{[1
]}

Lu, Suying ^{[1
]}

Sun, Feifei ^{[1
]}

Huang, Junting ^{[1
]}

Que, Yi ^{[1
]}

Zhang, Lian ^{[1
]}

Zhang, Yizhuo ^{[1
]}

Sun, Xiaofei ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e22009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e22009

引用

页数：3

共 50 条

[21] PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS IRINOTECAN AND TEMOZOLOMIDE FOR RELAPSED OR REFRACTORY NEUROBLASTOMA: PRELIMINARY RESULTS
Modak, Shakeel
Kushner, Brian H.
Kramer, Kim
Basu, Ellen
Roberts, Stephen S.
Cheung, Nai-Kong V.
PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1057 - 1057
[22] High-Dose Carboplatin-Irinotecan-Temozolomide (HD-CIT) for Relapsed and Refractory Neuroblastoma
Saida, Satoshi
Kozuki, Kagehiro
Kubota, Hirohito
Kawabata, Naoko
Kato, Itaru
Umeda, Katsutsugu
Hiramatsu, Hidefumi
Adachi, Souichi
Takita, Junko
PEDIATRIC BLOOD & CANCER, 2020, 67
[23] High-dose carboplatin-irinotecan-temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma
Kobushi, Hirokazu
Saida, Satoshi
Umeda, Katsutsugu
Iwai, Atsushi
Kozuki, Kagehiro
Kubota, Hirohito
Tanaka, Kuniaki
Obu, Satoshi
Uchihara, Yoshinori
Tasaka, Keiji
Kato, Itaru
Hiramatsu, Hidefumi
Takita, Junko
PEDIATRIC BLOOD & CANCER, 2023, 70 (07)
[24] Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma
Larrosa, Crstina
Simao Rafael, Margarida
Pablo Munoz, Juan
Gorostegui, Maite
Castaneda Heredia, Alicia
Garraus, Moira
Mora, Jaume
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[25] Therapy With Dinutuximab Beta in Combination With Chemotherapy in Patients With Refractory Relapsed Neuroblastoma. Initial Results
Wieczorek, A.
Zaniewska-Tekieli, A.
Gizycka, A.
Balwierz, W.
PEDIATRIC BLOOD & CANCER, 2020, 67 : S272 - S272
[26] The RIST design: A molecularly targeted multimodal approach for the treatment of patients with relapsed and refractory neuroblastoma.
Corbacioglu, Selim
Steinbach, Daniel
Lode, Holger N.
Gruhn, Bernd
Fruehwald, Michael
Broeckelmann, Mechthild
Suttorp, Meinolf
Escherich, Gabriele
Carlo, Gunnar
Ehlert, Karoline
Meister, Bernhard
Simon, Thorsten
Debatin, Klaus-Michael
Kuhlen, Michaela
Feddersen, Ise
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[27] Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors
Hernandez-Marques, C.
Lassaletta-Atienza, A.
Ruiz Hernandez, A.
Blumenfeld Olivares, J. A.
Arce Abaitua, B.
Cormenzana Carpio, M.
Madero Lopez, L.
ANALES DE PEDIATRIA, 2013, 79 (02): : 68 - 74
[28] Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients
Kim, Hyery
Kang, Hyoung Jin
Lee, Ji Won
Park, June Dong
Park, Kyung Duk
Shin, Hee Young
Ahn, Hyo Seop
CHILDS NERVOUS SYSTEM, 2013, 29 (10) : 1851 - 1858
[29] Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients
Hyery Kim
Hyoung Jin Kang
Ji Won Lee
June Dong Park
Kyung Duk Park
Hee Young Shin
Hyo Seop Ahn
Child's Nervous System, 2013, 29 : 1851 - 1858
[30] Randomized phase 2 trial of the combination of vincristine and irinotecan with or without temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS).
Defachelles, Anne Sophie
Bogart, Emilie
Casanova, Michela
Merks, Hans
Bisogno, Gianni
Calareso, Giuseppina
Melcon, Soledad Gallego
Gatz, Susanne
Le Deley, Marie-Cecile
McHugh, Kieran
Probst, Alicia
Rocourt, Nathalie
van Rijn, Rick R.
Wheatley, Keith
Minard-Colin, Veronique
Chisholm, Julia
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →